

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN

SITAXENTAN SODIUM

PRONUNCIATION

syeh' tax en' tan


THERAPEUTIC CLAIM

Treatment of congestive heart failure, ischemic deficits in patients with subarachnoid, treatment of hypertension, and treatment of prostate cancer (endothelin receptor antagonist; specific for the ET_A receptor)

CHEMICAL NAMES

1. 3-thiophenesulfonamide, *N*-(4-chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-5yl)acetyl], sodium salt
2. *N*-(4-chloro-3-methyl-5-isoxazolyl)-2-[[4,5-(methylenedioxy)-*o*-tolyl]acetyl]-3-thiophenesulfonamide, sodium salt

STRUCTURAL FORMULA



MOLECULAR FORMULA

C₁₈H₁₄ClN₂NaO₆S₂

MOLECULAR WEIGHT

476.9

TRADEMARK

None as yet

MANUFACTURER

Pfizer

CODE DESIGNATION

TBC-11251z; TBC-11251Na

CAS REGISTRY NUMBER

210421-74-2

NOTE: This statement supersedes adopted name *sitaxsentan sodium* (N99/62). The adoption of *sitaxsentan sodium* is hereby rescinded.